# Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

> **NCT00461045** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MRZ 0.5 mg/m^2

## Key facts

- **NCT ID:** NCT00461045
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00461045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00461045, "Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00461045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*